

**Updates on Retina Clinical Trials in 2025 - Featuring 16th P. Kenneth Nase Memorial Lecture**

**Saturday, April 5, 2025**

*Wills Eye Auditorium*

**Conference Description:**

[Click Here to Register for the Livestream](https://attendee.gotowebinar.com/register/349260309393892188)

The 16th P. Kenneth Nase Memorial Lecture will be delivered by David S. Boyer, MD of Retina-Vitreous Associates Medical Group in California.

David S. Boyer, M.D. is a Board-certified ophthalmologist specializing in the treatment of diseases of the retina and vitreous. He is Senior Partner at Retina-Vitreous Associates Medical Group with offices in Los Angeles, Beverly Hills, North Hollywood, Torrance, Pasadena, Tarzana, Glendale and La Mirada, California. Dr. Boyer is an Adjunct Clinical Professor of Ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, CA. He has an extensive research background and is currently an investigator for various clinical trials. He is one of the leading retinal clinical researchers in the country for new treatments in macular degeneration and diabetic macular edema. A widely-published author and avid lecturer, Dr. Boyer lectures nationally and internationally on retinal research and the innovative approach to the treatment of retinal diseases

Topics covered will include clinical trial design and clinical trial results. Dr. David Boyer will be delivering the Nase Lecture. His lecture will cover clinical trial results for Lumithera for treatment of dry AMD, Ophthea as an adjunct for treatment of wet AMD, and CNTF for treatment of idiopathic perifoveal telangiectasia.

With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.

**At the conclusion of the course, participants should be able to:**

0 Evaluate the use of Lumithera, a newly FDA-approved treatment for dry AMD.

1 Understand clinical trial design and the limitations of clinical trials.

3 Apply results of clinical trials to clinical practice.

4 Identify patients who are good candidates for clinical trials.

5 Recognize new and emerging therapies for various retinal diseases.

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Credit Statement Designation:**

Wills Eye Hospital designates this Live Activity for a maximum of 3.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Samir N Patel, MD | Faculty, Planner | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron (Relationship has ended) - 07/15/2024 |
| Meera Sivalingam, MD | Faculty | Nothing to disclose - 01/06/2025 |
| Allen Chiang, MD | Faculty | Grant or research support-Genentech|Grant or research support-Apellis Pharmaceuticals - 03/07/2025 |
| Carl D. Regillo, MD | Faculty | Consulting Fee-Allergan|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-EyePoint Pharmaceuticals|Consulting Fee-Genentech|Consulting Fee-Novartis|Consulting Fee-Ocugen|Consulting Fee-REGENXBIO, Inc.|Consulting Fee-Regeneron|Consulting Fee-Astellas Pharma|Consulting Fee-Ocular Therapeutix|Consulting Fee-Zeiss|Consulting Fee-Aderum Biotechnologies, Inc.|Consulting Fee-Alcon|Consulting Fee-Bausch + Lomb|Consulting Fee-Boehringer Ingelheim - 08/08/2024 |
| Joshua H Uhr, MD | Faculty, Planner | Public Corp Stock-Apellis Pharmaceuticals|Consulting Fee-Regeneron - 04/09/2024 |
| James P. Dunn, MD | Faculty | Nothing to disclose - 11/15/2024 |
| Allen Ho, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Alcon|Consulting Fee-Aerie Pharmaceuticals|Grant or research support-Aerie Pharmaceuticals|Consulting Fee-Aldeyra|Grant or research support-Aldeyra|Consulting Fee-Astellas Pharma|Consulting Fee-Atsena|Grant or research support-Atsena|Consulting Fee-Chengdu Kanghong Pharmaceutical|Grant or research support-Chengdu Kanghong Pharmaceutical|Consulting Fee-Clearside Biomedical|Consulting Fee-Annexon|Grant or research support-Annexon|Grant or research support-Astellas Pharma|Other: Equity-Covalent Medical, LLC|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Allergan|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Apellis Pharmaceuticals|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech|Independent Contractor (included contracted research)-Kodiak Sciences (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Notal Vision|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron|Membership on Advisory Committees or Review Panels, Board Membership, etc.-REGENXBIO, Inc.|Grant or research support-4DMT|Consulting Fee-Aavantgarde Bio|Consulting Fee-AcuSurgical|Consulting Fee-Adverum|Grant or research support-Adverum|Consulting Fee-Dompé |Consulting Fee-Emmecell|Consulting Fee-EyePoint Pharmaceuticals|Grant or research support-EyePoint Pharmaceuticals|Consulting Fee-Eyevensys|Consulting Fee-Janssen|Grant or research support-Janssen|Consulting Fee-Kiora|Grant or research support-Kiora|Consulting Fee-Lineage|Grant or research support-Lineage|Consulting Fee-Lumithera|Grant or research support-Lumithera|Consulting Fee-Nanoscope|Grant or research support-Nanoscope|Grant or research support-National Eye Institute|Consulting Fee-Notal Vision|Grant or research support-Notal Vision|Consulting Fee-Ocular Therapeutix|Consulting Fee-ONL|Other: Equity-ONL|Consulting Fee-Oxular|Grant or research support-ProQR|Consulting Fee-Stealth|Consulting Fee-Vanotech - 02/18/2025 |
| Duo Xu, MD | Faculty | Consulting Fee-Gyroscope Therapeutics|Advisor-Apellis|Consulting Fee-Bausch + Lomb|Consulting Fee-Zeiss|Consulting Fee-REGENXBIO, Inc.|Consulting Fee-Alimera Sciences (Relationship has ended) - 11/25/2024 |
| Anton Orlin, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Allergan (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Zeiss (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Apellis Pharmaceuticals (Relationship has ended) - 10/09/2024 |
| Michael Klufas, MD | Faculty, Planner | Consulting Fee-REGENXBIO, Inc.|Consulting Fee-Genentech|Consulting Fee-Regeneron|Honoraria-Coherus (Relationship has ended)|Honoraria-Biogen (Relationship has ended)|Consulting Fee-Abbvie|Grant or research support-Bausch + Lomb|Consulting Fee-Dutch Ophthalmic USA|Consulting Fee-Alimera Sciences - 11/29/2024 |
| David S Boyer, MD | Faculty | Consulting Fee-Acucela (Relationship has ended)|Consulting Fee-Aderum Biotechnologies, Inc.|Consulting Fee-Aerpio (Relationship has ended)|Consulting Fee-Alexion Pharmaceuticals|Consulting Fee-Allergan|Consulting Fee-Amgen|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-Astellas Pharma|Consulting Fee-Aura Biosciences|Consulting Fee-Bausch + Lomb|Consulting Fee-Bayer (Relationship has ended)|Consulting Fee-Boehringer Ingelheim|Consulting Fee-Chengdu Kanghong Pharmaceutical|Consulting Fee-Clearside Biomedical|Consulting Fee-EyePoint Pharmaceuticals|Consulting Fee-Genentech|Consulting Fee-Glaukos Corporation|Consulting Fee-Johnson & Johnson (Relationship has ended)|Consulting Fee-Kala Pharmaceuticals|Consulting Fee-Kodiak Sciences (Relationship has ended)|Consulting Fee-Neurotech|Consulting Fee-Notal Vision (Relationship has ended)|Consulting Fee-Novartis|Consulting Fee-Ocugen|Consulting Fee-Ocular Therapeutix|Consulting Fee-Ora, Inc.|Consulting Fee-Regeneron|Consulting Fee-REGENXBIO, Inc.|Consulting Fee-Sanofi|Consulting Fee-Santen Pharmaceuticals|Consulting Fee-Roche|Consulting Fee-Sun Pharmaceutical Industries|Consulting Fee-Unity Biotechnology|Consulting Fee-LumiThera - 03/11/2025 |
| Bita Momenaei, MD | Faculty | Nothing to disclose - 01/06/2025 |
| Sidra Zafar, MD | Peer Reviewer | Nothing to disclose - 11/23/2024 |
| Luis Acaba-Berrocal, MD | Peer Reviewer | Nothing to disclose - 01/04/2025 |
| Flavius Beca, MD | Peer Reviewer | Nothing to disclose - 11/26/2024 |
| Ari August, BA | Faculty | Nothing to disclose - 12/01/2024 |
| Brianna Kenney, BA | Faculty | Nothing to disclose - 02/17/2025 |

